Biologic injections sits at the center of this dementia and brain health question.
If you assume biologic injections for asthma are reserved for the sickest patients — those tethered to oxygen tanks or making frequent trips to the emergency room — the actual eligibility data tells a different story. Research shows that roughly 80.9% of uncontrolled asthma occurs in patients being treated for mild-to-moderate disease, not severe asthma. That means millions of people struggling with persistent symptoms, repeated flare-ups, or a growing dependence on oral steroids may qualify for biologic therapy and not know it. Globally, about 51% of adults with severe asthma are eligible for at least one biologic, and between 1.4% and 19.7% of patients with mild-to-moderate asthma also meet the criteria — a range that surprises even some physicians. Consider a 58-year-old woman with moderate asthma who has been on inhaled corticosteroids for years. She still wakes up coughing most nights and has needed two courses of prednisone in the past twelve months.
She does not think of herself as a candidate for advanced treatment. But under current prescribing guidelines, she may well be one. The landscape of biologic therapies has expanded dramatically, with seven FDA-approved options now available and a new class of drugs that does not even require high eosinophil counts for eligibility. This article covers who actually qualifies for biologic injections, what each drug targets, the newest approval that requires only two doses per year, what these treatments cost, and why the intersection of asthma and conditions like obesity or nasal polyps is reshaping who gets access to these medications. For readers of this site focused on brain health and dementia care, the connection is not abstract. Chronic uncontrolled asthma drives systemic inflammation, disrupts sleep architecture, and often leads to prolonged oral corticosteroid use — all factors linked to cognitive decline. Getting asthma under better control, especially for older adults or caregivers managing multiple conditions, has implications well beyond the lungs.
Table of Contents
- Who Actually Qualifies for Biologic Injections for Asthma — and Why It May Surprise You?
- The Seven FDA-Approved Biologics and What Each One Targets
- Why Tezepelumab Changed the Conversation for Hard-to-Classify Patients
- What Biologic Injections Cost and How to Navigate the Financial Reality
- Pediatric Eligibility and the Risks of Waiting Too Long
- The Asthma-Brain Health Connection That Caregivers Should Not Ignore
- What the Next Two Years Look Like for Biologic Asthma Treatment
- Conclusion
- Frequently Asked Questions
Who Actually Qualifies for Biologic Injections for Asthma — and Why It May Surprise You?
The traditional image of a biologic candidate is someone with severe, treatment-resistant asthma who has exhausted every other option. While that profile certainly qualifies, the real-world picture is far broader. Over 28 million Americans have asthma — roughly one in twelve people — and asthma remains uncontrolled in approximately 50% of children and 62% of adults. The general eligibility criteria require a confirmed asthma diagnosis with verified inhaler technique, uncontrolled symptoms despite medium-to-high dose inhaled corticosteroids plus a second controller medication, and typically a history of two or more exacerbations in the prior year or chronic oral corticosteroid use. Biomarker assessment — blood eosinophil count, fractional exhaled nitric oxide levels, and serum IgE — helps determine which biologic is the best fit. What catches many patients off guard is that comorbidities can open the door to eligibility. Nasal polyps, atopic dermatitis, chronic sinusitis, and even obesity can support a case for biologic therapy.
Applying obesity-adjusted criteria in one study expanded biologic eligibility by 11.3%, revealing a population that had been systematically overlooked. A person whose asthma seems “moderate” on paper but who also battles chronic sinus disease and carries excess weight may actually have a stronger case for biologics than someone with isolated severe asthma and no comorbidities. Perhaps most striking is how far real-world prescribing has moved beyond clinical trial boundaries. Fewer than one in ten U.S. patients currently receiving asthma biologics would have been eligible for the clinical trial of the biologic they use. Physicians are prescribing these drugs to a much wider range of patients than the original studies enrolled, and outcomes data supports their doing so. If your doctor has never raised the topic of biologics, it may be worth asking — especially if your asthma remains poorly controlled despite doing everything right with inhalers and controllers.
The Seven FDA-Approved Biologics and What Each One Targets
As of early 2026, seven biologic injections have received FDA approval for asthma, each targeting a different piece of the inflammatory cascade. Omalizumab (Xolair), the first to market in 2003, blocks immunoglobulin E and works best for allergic asthma. Mepolizumab (Nucala, approved 2015), reslizumab (Cinqair, approved 2016), and benralizumab (Fasenra, approved 2017) all target the interleukin-5 pathway to reduce eosinophils, though reslizumab is administered intravenously rather than by injection. Dupilumab (Dupixent, approved 2018) blocks interleukin-4 and interleukin-13, addressing both allergic and eosinophilic inflammation — a dual mechanism that also makes it effective for atopic dermatitis and nasal polyps. Tezepelumab (Tezspire, approved 2021) targets thymic stromal lymphopoietin upstream in the inflammatory process, making it the first biologic approved for broad asthma types regardless of phenotype. The newest addition is depemokimab (Exdensur), approved by the FDA on December 16, 2025. Manufactured by GSK, it is the first ultra-long-acting biologic for severe eosinophilic asthma, requiring only two subcutaneous injections per year — one 100 mg dose every 26 weeks.
In pivotal trials, depemokimab reduced asthma attacks by 58% in SWIFT-1 and 48% in SWIFT-2 over 52 weeks, with a pooled 72% reduction in exacerbations requiring hospitalization or emergency department visits. For patients aged 12 and older with severe eosinophilic asthma, the convenience factor alone is significant. Moving from monthly or bimonthly injections to twice yearly removes a major adherence barrier. However, having seven options does not mean any one of them is a good fit without proper workup. A patient with high eosinophils but normal IgE would be poorly served by omalizumab. Someone with T2-low asthma — where eosinophils and allergic markers are not elevated — would not respond to most of these drugs. The exception is tezepelumab, which does not require high eosinophil counts for eligibility, making it accessible to patients who fall outside the phenotypic boxes that other biologics demand. Matching the right drug to the right patient requires biomarker testing that not all primary care offices routinely perform, which is one reason referral to a specialist matters.
Why Tezepelumab Changed the Conversation for Hard-to-Classify Patients
Before tezepelumab’s approval, patients with T2-low or non-eosinophilic asthma were largely shut out of the biologic conversation. Their blood work did not show the elevated eosinophil counts or IgE levels required for the other five injectable options. They were told, in effect, that their asthma was not the right kind for advanced treatment — even when it was poorly controlled and eroding their quality of life. Tezepelumab works further upstream by blocking thymic stromal lymphopoietin, an epithelial cytokine that triggers multiple inflammatory pathways. Because it intervenes before the immune response branches into eosinophilic or allergic subtypes, it reduces exacerbations across a broader patient population. This matters in practical terms. A 45-year-old man with persistent asthma, normal eosinophils, normal IgE, but three emergency department visits in the past year previously had no biologic option.
With tezepelumab, he does. It also matters for the growing number of patients whose asthma overlaps with obesity-driven inflammation, where traditional biomarkers can be misleading. Obese patients often have lower eosinophil counts than their underlying disease activity would predict, creating a diagnostic blind spot that tezepelumab sidesteps entirely. The limitation is cost and access. Like other biologics, tezepelumab is expensive, and insurance coverage for patients who do not meet traditional biomarker thresholds can be harder to secure. Prior authorization battles are common, and some insurers still default to requiring evidence of eosinophilic inflammation before approving any biologic — a policy that has not caught up with the science. Patients and their physicians may need to appeal denials, sometimes more than once.
What Biologic Injections Cost and How to Navigate the Financial Reality
The financial barrier to biologic therapy is real. At U.S. wholesale acquisition cost, benralizumab runs approximately $30,889 per year, mepolizumab about $37,293, and dupilumab roughly $38,110. Omalizumab is the most variable, ranging from about $12,586 to $81,809 annually depending on the patient’s weight and IgE level. Most biologics cluster in the $30,000 to $40,000 per year range before insurance, and while depemokimab’s pricing was not yet widely benchmarked at the time of its approval, its positioning as a premium GSK product suggests it will land in a similar range. The tradeoff patients face is straightforward but painful: biologics can dramatically reduce exacerbations, emergency visits, and oral steroid dependence, but they require either robust insurance coverage or significant financial assistance.
The good news is that every manufacturer offers copay assistance cards for commercially insured patients, and patient assistance programs exist for those who are uninsured or underinsured. Some patients pay as little as zero dollars out of pocket through these programs, though navigating the paperwork takes effort. A practical comparison — the annual cost of repeated prednisone courses, emergency department visits, missed work, and the long-term health consequences of chronic oral corticosteroid use (including bone loss, diabetes risk, and cognitive effects) often rivals or exceeds the cost of a biologic when calculated honestly. A significant development on the horizon is Omlyclo (omalizumab-igec) by Celltrion, the first interchangeable biosimilar to Xolair, expected to be available in the United States by September 2026. Biosimilars have historically driven down costs in other drug classes, and an interchangeable designation means pharmacists can substitute it without physician intervention. For patients currently priced out of omalizumab or struggling with its highly variable annual cost, this could meaningfully expand access.
Pediatric Eligibility and the Risks of Waiting Too Long
One of the more underappreciated shifts in biologic prescribing is the expansion of eligibility to children. Children as young as six can now qualify for certain biologics, including omalizumab, mepolizumab, dupilumab, and tezepelumab. This is not a trivial development. Severe uncontrolled asthma in childhood drives airway remodeling — permanent structural changes to the lungs that no amount of future treatment can fully reverse. Early intervention with biologics, when indicated, may preserve lung function in ways that waiting until adulthood cannot. The warning here is against both overtreatment and undertreatment.
Not every child with asthma needs a biologic, and the long-term safety data in pediatric populations, while reassuring so far, is less extensive than in adults. But the opposite error — dismissing a child’s poorly controlled asthma as something they will “grow out of” while their airways quietly scar — carries its own serious consequences. Parents should be aware that asthma is uncontrolled in roughly half of children with the diagnosis, and that uncontrolled does not always look dramatic. A child who avoids sports, sleeps poorly, or uses a rescue inhaler several times a week may be a candidate for escalation that their current treatment plan is not providing. For families also managing dementia care for an older relative, the logistical burden of a child’s biologic therapy — specialist visits, injection schedules, insurance coordination — adds to an already strained caregiving load. The shift to longer-acting biologics like depemokimab, with its twice-yearly dosing, represents a genuine quality-of-life improvement for families juggling multiple medical needs.
The Asthma-Brain Health Connection That Caregivers Should Not Ignore
Chronic uncontrolled asthma has downstream effects on the brain that are relevant to anyone reading a site focused on dementia care and cognitive health. Repeated hypoxic episodes, systemic inflammation driven by eosinophilic or allergic pathways, and long-term oral corticosteroid use all contribute to cognitive risk. Prednisone and similar steroids, commonly prescribed during asthma exacerbations, are associated with hippocampal volume reduction, mood disturbance, and impaired memory when used chronically.
Biologics that reduce exacerbation frequency directly reduce the need for these steroid courses. For an older adult already showing early signs of cognitive decline, poorly managed asthma compounds the problem in ways that may not be immediately obvious to their care team. A 72-year-old with moderate asthma who qualifies for dupilumab and thereby avoids three or four courses of prednisone per year is not just breathing better — they are removing a repeated insult to an already vulnerable brain. This is a conversation worth having with both the pulmonologist and the neurologist, and it is one that too rarely happens across specialty silos.
What the Next Two Years Look Like for Biologic Asthma Treatment
The biologic pipeline for asthma is not slowing down. The approval of depemokimab in late 2025 signaled a new era of ultra-long-acting therapies, and the expected arrival of Omlyclo as an interchangeable biosimilar by September 2026 will begin to address the cost barrier that has kept biologics out of reach for many patients. Combination approaches — using biologics alongside other advanced therapies, or sequencing patients from one biologic to another based on response — are becoming more common and more systematically studied.
The broader trend is toward earlier intervention, wider eligibility, and treatment matched to individual inflammatory profiles rather than to arbitrary severity labels. For the estimated five to ten percent of asthma patients with truly severe disease, biologics have already been transformative. The next chapter is about the much larger group — the millions with moderate, poorly controlled asthma who have been told they are not sick enough for advanced treatment but whose daily lives, lung function, and long-term health tell a different story.
Conclusion
Biologic injections for asthma have moved well beyond a last-resort option for the most severe cases. With seven FDA-approved therapies targeting different inflammatory pathways, eligibility criteria that now encompass moderate disease, comorbidity-driven inflammation, and pediatric patients as young as six, the real surprise is how many people qualify and do not know it. The approval of depemokimab as a twice-yearly injection and the approaching availability of a biosimilar to Xolair both point toward a future where access and convenience continue to improve.
If you or someone you care for has asthma that remains poorly controlled despite consistent use of inhalers and controller medications — or if exacerbations keep requiring oral steroids — it is worth asking a specialist about biologic eligibility. This is particularly important for older adults and for anyone in a caregiving role where unmanaged respiratory disease adds cognitive risk on top of physical burden. A biomarker workup and an honest conversation about treatment goals can determine whether one of these therapies is appropriate, and the answer may genuinely surprise you.
Frequently Asked Questions
Do I have to have severe asthma to qualify for a biologic injection?
No. While biologics were originally developed for severe asthma, research shows that 80.9% of uncontrolled asthma occurs in patients with mild-to-moderate disease. Between 1.4% and 19.7% of mild-to-moderate asthma patients meet biologic eligibility criteria, particularly when comorbidities or persistent exacerbations are factored in.
How do doctors decide which biologic is right for a particular patient?
The decision is based primarily on biomarkers — blood eosinophil count, fractional exhaled nitric oxide, and serum IgE levels — along with the patient’s asthma phenotype, exacerbation history, and comorbidities. For example, high IgE and confirmed allergies point toward omalizumab, while elevated eosinophils favor mepolizumab, benralizumab, or depemokimab. Tezepelumab is the only option that does not require specific biomarker thresholds.
What is special about the newest biologic, depemokimab (Exdensur)?
Approved in December 2025, depemokimab is the first biologic requiring only two injections per year (every 26 weeks). In clinical trials, it reduced asthma exacerbations requiring hospitalization or emergency visits by 72% in pooled analysis. It is approved for patients aged 12 and older with severe eosinophilic asthma.
Can children receive biologic injections for asthma?
Yes. Children as young as six can qualify for omalizumab, mepolizumab, dupilumab, and tezepelumab, depending on their specific diagnosis and biomarker profile. Early treatment may help prevent permanent airway remodeling that occurs with chronic uncontrolled asthma in childhood.
How much do biologic injections cost, and is financial help available?
Most asthma biologics cost between $30,000 and $40,000 per year at wholesale, though omalizumab ranges from about $12,586 to $81,809 depending on dosing. Every manufacturer offers copay cards and patient assistance programs, and the expected arrival of a biosimilar to Xolair by September 2026 may lower costs further.
Is there a connection between uncontrolled asthma and cognitive decline?
Yes. Chronic uncontrolled asthma contributes to systemic inflammation, repeated hypoxic episodes, and frequent oral corticosteroid use — all factors associated with cognitive risk. Reducing exacerbation frequency through biologics can decrease reliance on steroids like prednisone, which are linked to hippocampal volume reduction and memory impairment with chronic use.
You Might Also Like
- The Drug Changing Lives of Spinal Muscular Atrophy Patients
- 11 Movements That May Aggravate a Herniated Disc According to Doctors
- 10 Facts Doctors Want Patients to Know About
For more, see NIH MedlinePlus — dementia.
